 |
answer text |
<p>The Medicines and Healthcare products Regulatory Agency (MHRA) operates a robust
programme of regulating and monitoring medicines to ensure patients have access to
safe and effective medicines. While the microbiome is still an evolving field, the
MHRA is working to further our understanding on the impact of pharmaceuticals on the
microbiome. Experts in MHRA are leading on international efforts to improve understanding
of this area, for example through the development of World Health Organisation reference
reagents for the microbiome.</p><p> </p><p>The potential impact of a chemical on plant
health, including soil microbiomes is already considered, as appropriate, as part
of the Health and Safety Executive (HSE)’s robust risk assessment process for pesticides
and for biocides.</p><p> </p><p>The legislation around veterinary medicines makes
it clear that when considering the authorisation of antimicrobial substances for use
in animals, there should be consideration of the impacts on the human, target animal,
and environmental microbiomes, including plants and soils.</p>
|
|
